Abstract
In this study, we constructed a quantitative structure activity relationship (QSAR) model of angiotensin I-converting enzyme (ACE) inhibitory tripeptides from published data (R2 = 0.8437; Q2 = 0.649) and applied the model to screen 27 tripeptides derived from cow milk protein sequences. Potential ACE inhibitory tripeptides were synthesised and evaluated in in vitro/in vivo studies. Results showed that ACE inhibitory activities of tripeptides followed the order (p < 0.05): isoleucine-proline-proline (IPP, commercial) > valine-isoleucine-proline (VIP) > isoleucine-valine-proline (IVP) based on concentrations (7.57–49.72 μm) that decreased 50% of ACE activity. Lowering systolic blood pressure (SBP) effect of tripeptides in rats (1.5 mg kg−1 body weight dosage) followed the order according to relative lowering SBP rates: IVP (24%) > IPP (17%) > VIP (12%), consistent with results on mRNA levels of sarcoplasmic reticulum Ca2+, Mg2+ -ATPase gene in rat hearts (p < 0.05). IPP and IVP showed no negative effects on blood glycometabolism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
